Abstracts tagged "Infection"

Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting
Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians
Rebecca Sharim¹, Leny Mathew², Michael George³, Preethi Thomas⁴ and Misha Rosenbach⁵, ¹Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…
Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting
Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Seoyoung C. Kim⁶, Daniel H. Solomon⁷ and Karen H. Costenbader^8,9, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…
Abstract Number: 1343 • 2015 ACR/ARHP Annual Meeting
Mortality Due to Sepsis in Patients with Rheumatoid Arthritis
Orit Barrett¹, Ella Abramovich², Jacob Dreiher³, Victor Novack⁴ and Mahmoud Abu-Shakra⁵, ¹Department of Medicine D, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ²Department of Medicine D, Soroka University Medical Center and Ben-Gurion University, Beersheba, Israel, ³Clalit Health Services, Ben-Gurion University of the Negev, Beer Sheva,,, BeerSheba, Israel, ⁴Clinical Research Center, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ⁵Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Severe infections contribute significantly to the morbidity and mortality of patients with rheumatoid arthritis. The aim of the study was to identify the characteristics…
Abstract Number: 3193 • 2015 ACR/ARHP Annual Meeting
Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Jonathan Miner¹, Lindsey Cook¹, Raeann Shimak², Julie Fox¹, Alissa Young¹, Kristen Monte², Subhajit Poddar², Michael Diamond¹ and Deborah Lenschow¹, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that has infected more than 1 million individuals in the Western Hemisphere since 2014. …
Abstract Number: 1346 • 2015 ACR/ARHP Annual Meeting
The Presentation and Outcomes of Surgically Treated Septic Arthritis: the Impact of Culture Results
Ziv Paz¹, Mary Louise Fowler², Clara Zhu³, Sarah B. Lieber¹, Andrew Moore⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²School of Medicine, Boston University School of Medicine, Boston, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Clinically-suspected septic arthritis is culture-negative in 18-43% of cases. These patients are often treated surgically with associated morbidity, prolonged hospital stays and high medical…
Abstract Number: 3238 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection
Adrian Richter¹, Anja Strangfeld², Prof. Dr. Matthias Schneider³, Thomas Klopsch⁴, Andreas Kapelle⁵, Jörg Kaufmann⁶, Angela Zink⁷ and Joachim Listing⁸, ¹German Rheumatism Research Center, Berlin, Germany, ²Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁴Rheumatologist in private practice, Neubrandenburg, Germany, ⁵Rheumatologist, Hoyerswerda, Germany, ⁶Medical practice specialising, Ludwigsfelde, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Tumor-necrosis-factor-α inhibition (TNFi) was assumed to be a relevant mechanism for the treatment of sepsis[1]. However, randomized controlled trials failed to show a survival…
Abstract Number: 1349 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes of Septic Bursitis
Sarah B. Lieber¹, Clara Zhu², Mary Louise Fowler³, Andrew Moore⁴, Robert H. Shmerling⁵ and Ziv Paz¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medical School, Boston University School of Medicine, Boston, MA, ³School of Medicine, Boston University School of Medicine, Boston, MA, ⁴Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Septic bursitis (SB) is a common condition that typically involves the olecranon and patellar bursae. It is unclear whether patients with SB treated surgically…
Abstract Number: 1357 • 2015 ACR/ARHP Annual Meeting
Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center
Yusuf Ziya Sener¹, Burak Yasin Aktas¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Ahmet Cagkan Inkaya³, Omer Karadag², Sule Apras Bilgen² and Sedat Kiraz², ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Infection Disease, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: CMV is a ubiquitous herpes virus associated with significant immunosuppression. Immunosuppressive treatments and ageing is well known risk factors for CMV reactivation. There are…
Abstract Number: 1450 • 2015 ACR/ARHP Annual Meeting
Clostridium Difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort
Daniel B. Horton^1,2,3, Brian L. Strom^1,3, Mary E. Putt³, Carlos D. Rose², David D. Sherry⁴ and Julia S. Sammons⁵, ¹Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Division of Pediatric Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, Infection Prevention and Control, Division of Infectious Diseases, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The incidence of Clostridium difficile infection (CDI) has increased among children, and CDI is associated with significant morbidity and mortality. Cases of C. difficile…
Abstract Number: 1521 • 2015 ACR/ARHP Annual Meeting
Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic
Renata Baronaite Hansen¹, Anne Brun Hesselvig², Rolf Magnus Arpi², Eva Kristin Jonassen¹, Gunhild Bukh¹ and Ole Rintek Madsen¹, ¹Department of Rheumatology/C, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Department of Clinical Microbiology, Department of Clinical Microbiology, Copenhagen University Hospital Herlev, Herlev, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) treated with biologic agents are at increased risk of infection. Therefore, screening for urinary tract infection (UTI) with urine…
Abstract Number: 1692 • 2015 ACR/ARHP Annual Meeting
Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Alan Menter³, Philip J. Mease⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, G James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor University Medical Center, Dallsa, TX, ⁴Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: To describe the rates of serious infections in psoriasis patients with psoriatic arthritis(PsA) from PSOLAR. Methods: PSOLAR is an international, disease-based, observational study in…
Abstract Number: 2032 • 2015 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Olga S. Zhukov¹, Rania W. Abolhosn¹, Jonnielyn G. Rivera¹, Mary Lape Nixon², Robert J. Lagier³, Harry E. Prince⁴, Hollis J. Batterman⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Lab Sciences, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Lab Services, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA
Background/Purpose: Chikungunya fever virus (CHIK) is emerging in the western hemisphere as a mosquito-borne, acute onset arthritis. The majority of cases progress to persistent moderate…
Abstract Number: 2034 • 2015 ACR/ARHP Annual Meeting
Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center
Barbara Goldstein¹, Jeffery J. Swigris², Shannon Kasperbauer¹, Pearlanne Zelarney¹ and JoAnn Zell¹, ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: National Jewish Health (NJH) is a tertiary referral center for pulmonary and immunologic disease. The infectious disease division at NJH specializes in the care…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2251 • 2015 ACR/ARHP Annual Meeting
Current Tobacco Use and the Rates of Postoperative Complications after Total Knee Arthroplasty
Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To our knowledge, well-designed studies that have examined the risk of post-arthroplasty implant-related complications after TKA with tobacco use are lacking. Our objective was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].